Sai Life SciencesNSE:SAILIFE +1.35%18 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 82.76% on this metric.
The historical rank and industry rank for Sai Life Sciences's OCF Margin % or its related term are showing as below:
NSE:SAILIFE'
s OCF Margin % Range Over the Past 10 Years
Min: 12.07 Med: 18.33 Max: 23.22
Current: 23.22
During the past 5 years, the highest OCF Margin % of Sai Life Sciences was 23.22%. The lowest was 12.07%. And the median was 18.33%.
NSE:SAILIFE's OCF Margin % is ranked better than 82.76% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs NSE:SAILIFE: 23.22
Sai Life Sciences OCF Margin % Related Terms
Sai Life Sciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences (NSE:SAILIFE) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sai Life Sciences and its competitors. Over the past decade, Sai Life Sciences' OCF Margin % has ranged from 12.07 to 23.22. According to the industry distribution chart, Sai Life Sciences ranks #35 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 17.2%.
Is Sai Life Sciences' OCF Margin % too high?
Sai Life Sciences' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 12.07 to a high of 23.22. Based on the distribution chart, Sai Life Sciences ranks #35 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #35 out of 203 companies for OCF Margin %. This places Sai Life Sciences in the top 17% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.67. Historically, Sai Life Sciences' own OCF Margin % has ranged from 12.07 to 23.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
